Skip to content

Prevention of Pneumonia in Children (age: 6 to 15 years) with HIV Infection

Prevention of Pneumonia in Children with HIV Infection - PPH-2

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2013/04/003535
Enrollment
100
Registered
2013-04-05
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- This study group consists of HIV positive Children in the age group (6-15 Years of age)

Interventions

Intervention1: Vaccines used : Pneumococcal Conjugate Vaccine (PCV-13 manufactured by Wyeth/Pfizer) and Hib Conjugate Vaccine (HibCV , manufactured by Serum Institute -India): Schedule : Two doses of

Sponsors

Indian Council of Medical Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Children 6-15 years of age known to have HIV infection with normal to moderate immune suppression who have not had the Hib or pneumococcal conjugate vaccine 2.Adult household member of child vaccinee 3.Sibling of child vaccinee

Exclusion criteria

Exclusion criteria: 1. Hospitalized children, 2. Child who presents with an acute illness on study day requiring hospitalization or inpatient short stay observation will be excluded. 3. Children with severe immune suppression 4. Children with an acute febrile illness with fever over 38 degrees Celsius will be excluded for vaccine on that study day. 5. Known previous immunization with HibCV or PCV. 6. Known contraindication to HibCV or PCV

Design outcomes

Primary

MeasureTime frame
1.Nasopharyngeal carriage rate of Hib and Pneumococcus for all vaccine recipients, adult household member and sibling living with vaccine recipient 2.Serotypes of pneumococcus isolated 3. Reported adverse events to vaccine recipientsTimepoint: All outcomes will be evaluated at 0, 2, 4, 6, 8, 10, 12 months after the 1st Visit (which is expected to be same as day of 1st dose of vaccines.

Secondary

MeasureTime frame
1. Immune response to the Hib Conjugate Vaccine based on ELISA 2. Antibiotic susceptibility of Hib and Pneumococcal isolates 3. Carriage rates of other co-colonizers in the nasopharynx specifically S. aureusTimepoint: All outcomes will be evaluated at 0, 2, 4, 6, 8, 10, 12 months after the 1st Visit (which is expected to be same as day of 1st dose of vaccines).

Countries

India

Contacts

Public ContactDr Subhasish Bhattacharyya MD DCH DNB

School of Medical Science and Technology , Indian Institute of Technology â??Kharagpur

arbik483@gmail.com03222283576

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026